Premium
High serum dihydrotestosterone examined by ultrasensitive LC ‐ MS / MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate‐specific antigen levels of 3–10 ng/ mL
Author(s) -
Miyoshi Y.,
Uemura H.,
Suzuki K.,
Shibata Y.,
Honma S.,
Harada M.,
Kubota Y.
Publication year - 2017
Publication title -
andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.947
H-Index - 43
eISSN - 2047-2927
pISSN - 2047-2919
DOI - 10.1111/andr.12294
Subject(s) - dihydrotestosterone , prostate cancer , medicine , urology , testosterone (patch) , prostate , prostate specific antigen , hyperplasia , androgen , biopsy , cancer , hormone
Summary There has been no consensus on the role of serum androgen concentrations in prostate cancer detection in men with prostate‐specific antigen levels of 3–10 ng/mL. In this study, testosterone and dihydrotestosterone concentrations in blood were examined by a newly developed method using ultrasensitive liquid chromatography with two serially linked mass spectrometers ( LC ‐ MS / MS ). We investigated the correlation between serum androgen levels and Gleason scores at biopsy. We analyzed data of 157 men with a total prostate‐specific antigen range of 3–10 ng/mL who underwent initial systematic prostate needle biopsy for suspected prostate cancer between April 2000 and July 2003. Peripheral blood testosterone and dihydrotestosterone concentrations were determined by LC ‐ MS / MS . Blood levels of testosterone and dihydrotestosterone were compared with pathological findings by multivariate analyses. Median values of prostate‐specific antigen and prostate volume measured by ultrasound were 5.7 ng/mL and 31.4 cm 3 , respectively. Benign prostatic hyperplasia was diagnosed in 97 patients (61.8%), and prostate cancer was diagnosed in 60 (38.2%) patients, including 31 (19.7%) patients with a Gleason score of 6 and 29 (18.5%) patients with a Gleason score of 7–10. Median values of testosterone and dihydrotestosterone in blood were 3798.7 and 371.7 pg/mL, respectively. There was a strong correlation between serum testosterone and dihydrotestosterone. In multivariate analysis, age, prostate volume, and serum dihydrotestosterone were significant predictors of benign prostatic hyperplasia or prostate cancer with a Gleason score of 6. The area under the receiver operating characteristics curve for age, prostate volume, and serum dihydrotestosterone were 0.67, 0.67, and 0.67, respectively . We confirmed that high dihydrotestosterone blood levels can predict benign prostatic hyperplasia or prostate cancer with a Gleason score of 6 in men with prostate‐specific antigen levels of 3–10 ng/mL.